| Literature DB >> 31817468 |
Sohyun Park1, Ji Eun Kang2,3, Hee Jung Choi4,5, Chung-Jong Kim4,6, Eun Kyoung Chung7,8, Sun Ah Kim9, Sandy Jeong Rhie1,2.
Abstract
Antimicrobial stewardship program (ASP) is one of the most important strategies for managing infectious disease treatment and preventing antimicrobial resistance. The successful implementation of ASP in the community health system (CHS) has been challenging. We evaluated perceptions of current ASP, potential setbacks of ASP implementation, and future demands on ASP services among physicians and pharmacists in the CHS. The qualitative research was conducted through in-depth individual interviews and focus group discussions with 11 physicians and 11 pharmacists. In addition, a quantitative gap analysis was conducted to assess the different awareness and demands on services of ASP and preferred antimicrobial-related problems (ARP). In overall, perceptions of ASP varied by profession. The identified setbacks were unorganized institutional leadership, the undefined roles of healthcare professionals, a lack of reimbursement, the hierarchical structure of the health system, and the labor-intensive working environment of pharmacy services. Although demands for ASP improvement were similar among professionals, they had different preferences in prioritizing each service item of ASP/ARP development and the profession responsible for each service. Continuous administrative and financial investments, understanding ASP contents, ASP-specific information technology, and interdisciplinary collaboration with good communication among healthcare professions are needed to continue the progression of ASP.Entities:
Keywords: antimicrobial stewardship program; community health system; interdisciplinary team; pharmacist
Year: 2019 PMID: 31817468 PMCID: PMC6963390 DOI: 10.3390/antibiotics8040252
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Gap analysis of the current status (left) and future preferred ASP services (right). a (a,b) means (number of pharmacists who answered “yes,” number of physicians who answered “yes”). ASP: antimicrobials stewardship programs.
Figure 2Gap analysis of the current situation (left) and future preferred ARP services that suggest pharmacists’ interventions (right). (a, b) means (the number of pharmacists who answered “yes”, the number of physicians who answered “yes”). ARP: antimicrobials-related problems.
Interviewees’ baseline characteristics.
| Characteristics | Physicians | Pharmacists | |
|---|---|---|---|
| Gender | Male | 7 | 0 |
| Female | 4 | 11 | |
| Age (years) | 26–35 | 1 | 5 |
| 36–45 | 7 | 4 | |
| 46–55 | 3 | 2 | |
| Work experience (years) | ≤5 | 1 | 0 |
| 6–10 | 3 | 6 | |
| 11–15 | 4 | 3 | |
| 16–20 | 2 | 2 | |
| ≥21 | 1 | 0 | |
| Employment | Community-based hospital | 11 | 11 |
| Medical subspecialty | Infection | 5 | NA |
| Pulmonary * | 4 | NA | |
| Hematology | 1 | NA | |
| Cardiology | 1 | NA | |
N/A, not applicable. * Two of pulmonologists are in charge of intensive care.
Questions in the gap analysis about ASP and ARP.
| Services | Is the Service Currently Performed? | Is the Service Preferred to Develop or Improve in the Future? |
|---|---|---|
|
| ||
| a. Prospective audit with direct intervention and feedback | □ Yes □ No | □ Yes □ No |
| b. Formulary restriction and preauthorization requirements | □ Yes □ No | □ Yes □ No |
| c. Education | □ Yes □ No | □ Yes □ No |
| d. Evidence-based guidelines and clinical pathways | □ Yes □ No | □ Yes □ No |
| e. Antimicrobial cycling | □ Yes □ No | □ Yes □ No |
| f. Antimicrobial order forms | □ Yes □ No | □ Yes □ No |
| g. Combination therapy | □ Yes □ No | □ Yes □ No |
| h. Streamlining or de-escalation of therapy | □ Yes □ No | □ Yes □ No |
| i. Dose optimization | □ Yes □ No | □ Yes □ No |
| j. Parenteral-to-oral conversion | □ Yes □ No | □ Yes □ No |
|
| ||
| a. Medications with no medical indication | □ Yes □ No | □ Yes □ No |
| b. Medical conditions for which there is no medication prescribed | □ Yes □ No | □ Yes □ No |
| c. Medications prescribed inappropriately for a particular medical condition | □ Yes □ No | □ Yes □ No |
| d. Inappropriate medication dose, dosage form, schedule, route of administration, or method of administration | □ Yes □ No | □ Yes □ No |
| e. Therapeutic duplication | □ Yes □ No | □ Yes □ No |
| f. Prescribing of medications to which the patient is allergic | □ Yes □ No | □ Yes □ No |
| g. Actual and potential adverse drug events | □ Yes □ No | □ Yes □ No |
| h. Actual and potential clinically significant drug–drug, drug–disease, drug–nutrient, and drug–laboratory test interaction | □ Yes □ No | □ Yes □ No |
| i. Failure to receive the full benefit of prescribed medication therapy | □ Yes □ No | □ Yes □ No |
| j. Problems arising from the financial impact of medication therapy on the patient | □ Yes □ No | □ Yes □ No |
| k. Failure of the patient to adhere to the medication regimen | □ Yes □ No | □ Yes □ No |
IPC/ASP, infection prevention, and control programs/antimicrobial stewardship programs; ARP, antimicrobial-related problems.